colorectal cancer
Conditions
Interventions
Group 1:Intravenous anesthesia
Group 2:Intravenous anesthesia + lidocaine
Group 3:Ihalation anesthesia
Group 4:Inhalation anesthesia + lidocaine
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Preoperative diagnosis of colorectal cancer, including: left colon tumor, right colon tumor, transverse colon tumor, sigmoid colon tumor and rectal cancer, TNM clinical stage: stage II, patients with laparoscopic radical colorectal resection ; 2. ASA grade I, II or III; Aged 18-70 years; 3. During the preoperative screening and evaluation, the principal investigator and the assisting investigators, the patients can understand and comply with the research protocol, can communicate, and agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Distant metastasis of colorectal tumor; 2. Preoperative neoadjuvant chemotherapy or radiotherapy; 3. Pregnant patients; 4. Hypersensitivity to lidocaine, ropivacaine, sufentanil, rocuronium bromide and other related anesthetics; 5. Long-term use of beta-blockers in the past; 6. Patients with chronic inflammatory disease or autoimmune disease before surgery, or previous long-term treatment with glucocorticoids or other immunosuppressive agents; 7. Preoperative coagulation dysfunction; 8. Preoperatively accompanied by severe heart disease (NYHA cardiac function class>3), severe renal insufficiency (serum creatinine>1.8mg/dL (159.1µmol/L) or receiving renal function replacement therapy), severe hepatic insufficiency (modified Child-Pugh class C); 9. Acute infection is not well controlled before surgery; with diabetes, preoperative blood sugar control is poor (fasting blood sugar control exceeds the range of 3.9-13.8mmol/L); 10. A history of drug abuse such as opioids; 11. Mental illness or cognitive dysfunction, inability to cooperate and poor compliance; 12. Patients with other contraindications to anesthesia or surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma NETosis-specific markers (MPO and H3Cit);Tumor progression and metastasis related markers (VEGF-A, MMP-3, MMP-9); | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain during activity 24 hours after surgery (definition: activity: when taking 3 deep breaths or 1 coughing; moderate to severe pain: NRS score >= 4);Incidence of adverse reactions 24 hours after surgery (such as nausea, vomiting, respiratory depression (respiratory rate less than 8 breaths/min), incidence of constipation);Incidence of moderate to severe pain at rest 24 hours after surgery;24h postoperative rehabilitation quality score (15-item Quality of Rehabilitation Rating Scale (QoR-15)), incidence of respiratory complications during postoperative hospitalization, incidence of chronic pain at 3 months, 6 months and 1 year after surgery, Hospitalization days, hospitalization expenses, etc.; | — |
Countries
China
Contacts
Public ContactBo Lulong
Shanghai Changhai Hospital
Outcome results
None listed